ARTICLE
11 February 2024

FDA Issues Final QMSR Rule For Medical Devices

E
Exponent

Contributor

In an era of accelerating change, Exponent is the only premium engineering and scientific consulting firm with the depth and breadth of expertise to solve our clients’ most profoundly unique, unprecedented, and urgent challenges.

Exponent brings together 90+ technical disciplines and 950+ consultants to help our clients navigate the increasing complexity of more than a dozen industries, connecting decades of pioneering work in failure analysis to develop solutions for a safer, healthier, more sustainable world.

New quality management system regulation rule harmonizes US regulations with international standard, reducing regulatory burden for device manufacturers.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

New quality management system regulation rule harmonizes US regulations with international standard, reducing regulatory burden for device manufacturers

On Jan. 31, the Food and Drug Administration issued the Quality Management System Regulation Final Rule to support global harmonization in medical device regulation in an effort to provide effective, safe, and high-quality medical devices for patients. The rule was published on Feb. 2.

The announcement finalizes FDA's proposed rule to amend the current good manufacturing practice (cGMP) requirements for medical devices under the Quality System (QS) regulation, in 21 CFR 820, to harmonize with ISO 13485:2016 Medical devices — Quality management systems — Requirements (ISO 13485) for regulatory purposes, the international consensus standard for medical devices.

Specifically, the final rule amends the title and incorporates the quality management system requirements for medical devices established by ISO 13485, creating a new regulation: the Quality Management System Regulation (QMSR).

What does this mean for medical device manufacturers?

FDA's alignment of a medical device manufacturer's quality management system with the international standard should:

  1. Streamline regulatory processes for manufacturers to meet requirements by multiple regulatory authorities
  2. Increase efficiencies for manufacturers already in compliance with the ISO standard

However, because ISO 13485 requires application of a risk-based approach in establishing and maintaining all aspects of a quality management system (QMS), the final rule is expected to have an impact on risk management practices for medical device manufacturers. In addition, FDA has stated in its FAQs that it will develop a new inspection process to align with the requirements of the new QMSR, which will affect manufacturers once inspections under the new regulation begin.

FDA has also edited part 4 (21 CFR part 4) to clarify the device QMS requirements for combination products.

The rule will be effective Feb. 2, 2026, allowing device manufacturers and importers two years to assess their current systems, processes, and procedures and implement any necessary changes to meet the requirements of the QMSR rule. Manufacturers are required to comply with the existing Quality System regulation until the new rule takes effect.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More